{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Sandoz and Momenta Pharmaceuticals immediately initiate sales of generic drug Glatopa after federal appeals court again invalidates patent for brand-name multiple sclerosis drug Copaxone; decision is serious blow to Teva Pharmaceutical; generic will cost 18 percent less than Copaxone, but will still cost patients more than $63,000 per year.", "type_of_material": "News", "word_count": "557", "lead_paragraph": "A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical\u2019s big-selling drug, Copaxone, which can cost $60,000 a year.", "pub_date": "2015-06-19T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Teva Ruling Clears Way for Generic Version of Multiple Sclerosis Drug", "print_headline": "Teva Loses Patent Case on Lucrative Multiple Sclerosis Drug"}, "snippet": "A federal appeals court on Thursday again invalidated a patent protecting Teva Pharmaceutical\u2019s big-selling drug, Copaxone, which can cost $60,000 a year.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/06/19/business/ruling-may-clear-way-for-generic-version-of-multiple-sclerosis-drug.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Generic Brands and Products", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Multiple Sclerosis", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Teva Pharmaceutical Industries Ltd", "name": "organizations"}, {"rank": "5", "is_major": "Y", "value": "Sandoz International GmbH", "name": "organizations"}, {"rank": "6", "is_major": "Y", "value": "Momenta Pharmaceuticals Inc", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Inventions and Patents", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Novartis AG", "name": "organizations"}], "blog": [], "_id": "5583120b38f0d85931d0d443", "source": "The New York Times"}